Remove 3 cannabis-hemp
article thumbnail

Attorney Fees Denied Due to Lack of Support in Cannabis Litigation Record

The IP Law Blog

In 2018, United Cannabis Corporation (“UCANN”) sued Pure Hemp Collective (“Pure Hemp”) for infringement of U.S. 9,730,911 (the “‘911 patent”), entitled “Cannabis Extracts and Methods of Preparing and Using the Same. comprising cannabinoids obtained by extraction from cannabis.” First, under 35 U.S.C. §

article thumbnail

Advertising for CBD – Safe for Broadcasters?

Broadcast Law Blog

CBD, short for cannabidiol, is a derivative of the Cannabis sativa plant. Industrial hemp is produced from portions of a strain of the same plant containing low concentrations of the psychoactive chemical known as THC, or tetrahydrocannabinol, and hemp can also be used to produce CBD.

Legal 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Looking at “Legal” Marijuana and CBD Advertising – A Presentation on the Issues

Broadcast Law Blog

Perhaps some of the most controversial areas in broadcast advertising are those surrounding the advertising of cannabis products. At the same time, the Federal government has recently decriminalized the possession of various hemp products with less than.3% 3% THC (the active ingredient in marijuana) in the 2018 Farm Act.

Legal 40
article thumbnail

HP&M’s Larry Houck Presenting “HHS’ Cannabis Rescheduling Recommendation: A Long Strange Trip with Potholes”

FDA Law Blog

. — In October 2022 President Joseph Biden directed the Secretary of Health and Human Services (“HHS”) and the Attorney General to begin the administrative process of reviewing expeditiously how cannabis is scheduled under federal law. Hyman, Phelps & McNamara, P.C., Hyman, Phelps & McNamara, P.C.,

article thumbnail

Joint Basis for FDA/HHS Marijuana Rescheduling Recommendation Unveiled

FDA Law Blog

The mostly redacted, then publicly available letter accompanying the basis for the recommendation stated that FDA was making a recommendation about marijuana, referring to botanical cannabis ( Cannabis sativa L.) 29, 2023). “Marijuana,” subject to the rescheduling recommendation, means all parts of the plant Cannabis sativa L.,

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog

The wide range of assertions supporting or opposing Health and Human Services’ (“HHS’”) recommendation that the Drug Enforcement Administration (“DEA”) reschedule cannabis federally from schedule I to schedule III would lead an outsider to conclude that commenters are referring to different substances.